Impacts of pharmacists-managed outpatient clinic in patients with hepatitis c virus infection: A retrospective study in China
Main Article Content
Keywords
Pharmacists, Pharmaceutical Clinic, Drug-related problems, Hepatitis C virus infection, Hepatitis C virus infection, China, Retrospective study
Abstract
Objective: Pharmacists are health care professionals who are actively involved in identifying and solving drug-related problems (DRPs) in patients with hepatitis C virus (HCV) infection. However, the effectiveness of pharmaceutical services at outpatient clinic for patients with HCV infection have not been reported in China. This study aims to describe and investigate the impacts of pharmacists-managed outpatient clinic in patients with HCV infection. Methods: We conducted a descriptive and retrospective study between May 2020 and April 2022. In order to give full play to the efficacy of directacting antivirals (DAAs), we established a referral process for HCV patients with DAAs. Doctors prescribed DAAs for HCV-infected outpatients, and then transferred them to the outpatient clinic managed by pharmacists. Pharmacists cooperated to complete the pharmaceutical monitoring of DAAs treatment for patients. The pharmacist conducted a comprehensive evaluation of the patient’s medication and developed planned intervention measures based on identified DRPs. Results: A total of 473 eligible patients participated in 851 pharmaceutical care. A total of 518 DRPs were identified (an average of 1.1 per patient). Treatment effectiveness (48.8%) was the most common DRP. The most commonly recommended intervention was changing the drug (18.3%). There were 97.1% patients accepting the interventions and 93.05% patients completely implemented. The overall sustained virologic response at week 12 posttreatment (SVR12) rate was 98.5% (466/473). The most cost-effective treatment was selected in 98.7% of patients. Conclusions: We confirmed that pharmacists had a valuable role to perform pharmacy services for HCV-infected outpatients. The intervention of pharmacists is effective in solving the DRPs and saving drug costs.
References
2. Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396-415. https://doi.org/10.1016/s2468-1253(21)00472-6
3. Chinese Society of Hepatology; Chinese Society of Infectious Diseases, Chinese Medical Association. [Guidelines for the prevention and treatment of hepatitis C (2019 version)]. Zhonghua Gan Zang Bing Za Zhi. 2019;27(12):962-979.
4. European Association for the Study of the Liver. Electronic address: [email protected]; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461-511.
5. The National Healthcare Secruity Adminstration.The National Medical Insurance Administration and the Ministry of Human Resources and Social Security issued the list of drugs for entry into the National Medical insurance negotiation in 2019.Accessed November 28, 2019.
6. Kiser JJ, Flexner C. Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49.
7. Downes JM, Donovan A, McAdam-Marx C. Pharmacist-led drug therapy management for hepatitis C at a federally qualified health care center. J Am Pharm Assoc (2003). 2022;62(5):1596-1605. https://doi.org/10.1016/j.japh.2022.04.014
8. Hayes CN, Imamura M, Tanaka J, et al. Road to elimination of HCV: Clinical challenges in HCV management. Liver Int. 2022;42(9):1935-1944. https://doi.org/10.1111/liv.15150
9. Sebhatu P, Martin MT. Genotype 1 hepatitis C virus and the pharmacist’s role in treatment. Am J Health Syst Pharm. 2016;73(11):764-74. https://doi.org/10.2146/ajhp150704
10. Hanna J, Sufian J, Suh JS, et al. Hepatitis C virus micro-elimination within a clinic for people with HIV: challenges in the home stretch. HIV Med. 2022;23(7):801-6. https://doi.org/10.1111/hiv.13241
11. Olea A Jr, Grochowski J, Luetkemeyer AF, et al. Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection. Integr Pharm Res Pract. 2018;7:105-111. https://doi.org/10.2147/iprp.s169282
12. Yamamoto H, Ikesue H, Ikemura M, et al. Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis. J Pharm Health Care Sci. 2018;4:17. https://doi.org/10.1186/s40780-018-0113-3
13. Chamorro-de-Vega E, Rodriguez-Gonzalez CG, Gimenez-Manzorro A, et al. Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct-acting antivirals: The GRUviC project. Int J Clin Pract. 2017;71(8). https://doi.org/10.1111/ijcp.12988
14. Pharmaceutical Care Network Europe Foundation. PCNE Classification for drug related problems version 9.1 2021.https://www.pcne.org/upload/files/449-2021-01-27-Report-online-validation-PCNE-classification-v9.1.pdf
15. Jebb AT, Ng V, Tay L. A Review of Key Likert Scale Development Advances: 1995-2019. Front Psychol. 2021;12:637547. https://doi.org/10.3389/fpsyg.2021.637547
16. Hirsch JD, Steers N, Adler DS, et al. Primary care-based, pharmacist-physician collaborative medication-therapy management of hypertension: a randomized, pragmatic trial. Clin Ther. 2014;36(9):1244-54. https://doi.org/10.1016/j.clinthera.2014.06.03017. Krass I, Walker AT, Watts GF. Detection and care of familial hypercholesterolaemia in the community: is there a role for the
pharmacist? Int J Clin Pharm. 2012;34(4):501-5. https://doi.org/10.1007/s11096-012-9646-y18. Lum ZK, Chang KL, Tsou KY, et al. Enhancing diabetes care with community pharmacist-involved collaborative care model: A multicentre
randomised controlled trial. Diabetes Res Clin Pract. 2022;185:109238. https://doi.org/10.1016/j.diabres.2022.109238
19. Gums TH, Carter BL, Milavetz G, et al. Physician-pharmacist collaborative management of asthma in primary care. Pharmacotherapy. 2014;34(10):1033-42. https://doi.org/10.1002/phar.1468
20. Samuel O, Unonu JM, Dotson K, et al. Interdisciplinary Care Team with Pharmacist in a Community-based HIV Clinic. J Natl Med Assoc. 2018;110(4):378-383. https://doi.org/10.1016/j.jnma.2017.07.005
21. Kiser JJ, Burton JR Jr, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10(10):596-6. https://doi.org/10.1038/nrgastro.2013.106
22. Margusino-Framiñán L, Cid-Silva P, Giménez-Arufe V, et al. Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus. Eur J Hosp Pharm. 2021;28(1):16-21. https://doi.org/10.1136/ejhpharm-2019-001889
23. Sicras-Mainar A, Morillo-Verdugo R. Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection. J Int Med Res. 2020;48(10):300060520964659.https://doi.org/10.1177/0300060520964659
24. Briggs AL. Pharmacists’ increasing involvement in hepatitis C management and prevention. J Am Pharm Assoc (2003).2018;58(1):5-6. https://doi.org/10.1016/j.japh.2017.12.008
25. Gao LH, Nie QH, Zhao XT. Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C. Int J Gen Med. 2021;14:289-301. https://doi.org/10.2147/ijgm.s283910
26. Dietz C, Maasoumy B. Direct-Acting Antiviral Agents for Hepatitis C Virus Infection-From Drug Discovery to Successful Implementation in Clinical Practice. Viruses. 2022;14(6):1325. https://doi.org/10.3390/v14061325
27. Zeuzem S, Serfaty L, Vierling J, et al. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol. 2018;53(5):679-688. https://doi.org/10.1007/s00535-018-1429-3
28. Puoti M, Foster GR, Wang S, et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol. 2018;69(2):293-300. https://doi.org/10.1016/j.jhep.2018.03.007
29. Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J ed. 2015;373(27):2618-28. https://doi.org/10.1056/nejmoa1512614
30. Ajlan AA, Al-Gain R, Ahmed M, et al. Developing a multidisciplinary HCV direct-acting antivirals utilization management and assessment program. J Am Pharm Assoc (2003). 2021;61(2):e159-e170. https://doi.org/10.1016/j.japh.2020.11.008
31. Huntley M, McCall K, Stickney K, et al. Avoidance of drug interactions with hepatitis C treatment: Evaluation of pharmacist interventions in the specialty setting. J Am Pharm Assoc. (2003). 2022;62(5):1671-1674. https://doi.org/10.1016/j.japh.2022.04.015
32. Kuo MH, Tseng CW, Lee CH, et al. Identification and management of contraindicated drug-drug interactions through pharmaceutical care programs: Experience in direct-acting antivirals therapy. J Formos Med Assoc. 2022;121(1 Pt 1):58-65.https://doi.org/10.1016/j.jfma.2021.01.008
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.